Investor Webinar: Telix Therapeutics Urology Showcase and Expert Forum
Telix Pharmaceuticals (ASX/Nasdaq: TLX) announces an upcoming investor webinar focused on its urologic oncology portfolio. The educational session will feature presentations from three global experts discussing the company's late-stage and next-generation radiotherapeutic candidates.
The panel includes: Dr. Neeraj Agarwal presenting on the ProstACT Global Phase 3 trial of TLX591 for prostate cancer; Dr. Eric Jonasch discussing the STARLITE studies of TLX250 in combination with immunotherapy for clear cell renal cell carcinoma; and Dr. Rodney Hicks covering TLX592 and targeted alpha therapies in prostate cancer treatment.
The 1.5-hour webinar is scheduled for Tuesday, March 11, 2025, at 5:30 PM EDT (Wednesday, March 12, 8:30 AM AEDT).
Telix Pharmaceuticals (ASX/Nasdaq: TLX) annuncia un prossimo webinar per investitori focalizzato sul suo portafoglio di oncologia urologica. La sessione educativa presenterà interventi di tre esperti globali che discuteranno dei candidati radioterapici in fase avanzata e di nuova generazione dell'azienda.
Il panel include: Dr. Neeraj Agarwal che presenterà il trial globale di Fase 3 ProstACT di TLX591 per il cancro alla prostata; Dr. Eric Jonasch che discuterà degli studi STARLITE di TLX250 in combinazione con l'immunoterapia per il carcinoma a cellule renali a cellule chiare; e Dr. Rodney Hicks che tratterà TLX592 e le terapie alfa mirate nel trattamento del cancro alla prostata.
Il webinar di 1,5 ore è programmato per martedì 11 marzo 2025, alle 17:30 EDT (mercoledì 12 marzo, 8:30 AEDT).
Telix Pharmaceuticals (ASX/Nasdaq: TLX) anuncia un próximo seminario web para inversores centrado en su cartera de oncología urológica. La sesión educativa contará con presentaciones de tres expertos globales que discutirán los candidatos radioterapéuticos en etapa avanzada y de nueva generación de la empresa.
El panel incluye: Dr. Neeraj Agarwal presentando el ensayo global de Fase 3 ProstACT de TLX591 para el cáncer de próstata; Dr. Eric Jonasch discutiendo los estudios STARLITE de TLX250 en combinación con inmunoterapia para el carcinoma de células renales de células claras; y Dr. Rodney Hicks cubriendo TLX592 y terapias alfa dirigidas en el tratamiento del cáncer de próstata.
El seminario web de 1,5 horas está programado para el martes 11 de marzo de 2025, a las 5:30 PM EDT (miércoles 12 de marzo, 8:30 AM AEDT).
Telix Pharmaceuticals (ASX/Nasdaq: TLX)는 비뇨기 종양학 포트폴리오에 초점을 맞춘 투자자 웨비나를 곧 개최한다고 발표했습니다. 이 교육 세션에서는 회사의 후기 단계 및 차세대 방사선 치료 후보에 대해 논의하는 세 명의 글로벌 전문가의 발표가 포함됩니다.
패널에는 Dr. Neeraj Agarwal이 전립선암을 위한 TLX591의 ProstACT 글로벌 3상 시험에 대해 발표하고; Dr. Eric Jonasch가 투명세포 신세포암을 위한 면역요법과 함께 TLX250의 STARLITE 연구에 대해 논의하며; Dr. Rodney Hicks가 전립선암 치료에서 TLX592 및 표적 알파 요법을 다룰 예정입니다.
1.5시간 웨비나는 2025년 3월 11일 화요일 오후 5시 30분 EDT (2025년 3월 12일 수요일 오전 8시 30분 AEDT)로 예정되어 있습니다.
Telix Pharmaceuticals (ASX/Nasdaq: TLX) annonce un prochain webinaire pour investisseurs axé sur son portefeuille d'oncologie urologique. La session éducative comprendra des présentations de trois experts mondiaux discutant des candidats radiothérapeutiques en phase avancée et de nouvelle génération de l'entreprise.
Le panel comprend : Dr. Neeraj Agarwal présentant l'essai mondial de phase 3 ProstACT de TLX591 pour le cancer de la prostate; Dr. Eric Jonasch discutant des études STARLITE de TLX250 en combinaison avec une immunothérapie pour le carcinome à cellules rénales claires; et Dr. Rodney Hicks abordant TLX592 et les thérapies alpha ciblées dans le traitement du cancer de la prostate.
Le webinaire de 1,5 heure est prévu pour le mardi 11 mars 2025, à 17h30 EDT (mercredi 12 mars, 8h30 AEDT).
Telix Pharmaceuticals (ASX/Nasdaq: TLX) kündigt ein bevorstehendes Investoren-Webinar an, das sich auf sein urologisches Onkologie-Portfolio konzentriert. Die Bildungssitzung wird Präsentationen von drei globalen Experten umfassen, die über die späten Stadien und die nächsten Generationen von radiotherapeutischen Kandidaten des Unternehmens sprechen.
Das Panel umfasst: Dr. Neeraj Agarwal, der über die ProstACT globale Phase 3-Studie zu TLX591 bei Prostatakrebs präsentiert; Dr. Eric Jonasch, der die STARLITE-Studien zu TLX250 in Kombination mit Immuntherapie bei klarzelligem Nierenkarzinom diskutiert; und Dr. Rodney Hicks, der TLX592 und gezielte Alpha-Therapien bei der Behandlung von Prostatakrebs behandelt.
Das 1,5-stündige Webinar ist für Dienstag, den 11. März 2025, um 17:30 Uhr EDT (Mittwoch, den 12. März, 8:30 Uhr AEDT) geplant.
- Multiple late-stage therapeutic candidates in development
- Presentation by prominent medical experts from leading institutions
- Diverse oncology pipeline targeting both prostate and kidney cancers
- None.
MELBOURNE, Australia and INDIANAPOLIS, March 04, 2025 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, Nasdaq: TLX, Telix, the Company) invites investors to join a webinar showcasing the Company’s late-stage and next-generation radiotherapeutic candidates in urologic oncology.
In this education session, Telix and global key opinion leaders will provide an overview on the development of its therapeutic candidates in prostate and kidney cancers:
- Neeraj Agarwal, MD, Professor of Medicine and Presidential Endowed Chair of Cancer Research at Huntsman Cancer Institute in Salt Lake City, UT, will discuss the ProstACT Global Phase 3 trial of TLX591 (177Lu rosopatamab tetraxetan), Telix’s lead radio antibody-drug conjugate (rADC) therapy candidate in prostate cancer.
- Eric Jonasch, MD, Professor of Medicine in the Department of Genitourinary Medical Oncology at MD Anderson Cancer Center in Houston, TX, will discuss the STARLITE studies of TLX250 (177Lu girentuximab) in combination with immunotherapy, in clear cell renal cell carcinoma.
- Rodney Hicks, MD, Professor of Medicine at the University of Melbourne and Monash University; Founder, Chair, and Chief Medical Officer at the Melbourne Theranostic Innovation Centre in Australia, will discuss TLX592 (64Cu/225Ac RADmAb®) and the role of targeted alpha therapies in the treatment of prostate cancer.
The webinar will be held on:
EDT: Tuesday March 11, 5.30pm
AEDT: Wednesday March 12, 8.30am
The event will run for approximately 1.5 hours.
Participants can register for the webcast at the following link: https://edge.media-server.com/mmc/p/39s4k7gw\
About Telix Pharmaceuticals Limited
Telix is a biopharmaceutical company focused on the development and commercialization of therapeutic and diagnostic radiopharmaceuticals and associated medical technologies. Telix is headquartered in Melbourne, Australia, with international operations in the United States, Canada, Europe (Belgium and Switzerland), and Japan. Telix is developing a portfolio of clinical and commercial stage products that aims to address significant unmet medical needs in oncology and rare diseases. ARTMS, IsoTherapeutics, Lightpoint, Optimal Tracers and RLS are Telix Group companies. Telix is listed on the Australian Securities Exchange (ASX: TLX) and the Nasdaq Global Select Market (Nasdaq: TLX). TLX591, TLX592 and TLX250 have not received a marketing authorization in any jurisdiction.
Visit www.telixpharma.com for further information about Telix, including details of the latest share price, ASX and SEC filings, investor and analyst presentations, news releases, event details and other publications that may be of interest. You can also follow Telix on LinkedIn, X and Facebook.
Telix Investor Relations
Ms. Kyahn Williamson
Telix Pharmaceuticals Limited
SVP Investor Relations and Corporate Communications
Email: kyahn.williamson@telixpharma.com
This announcement has been authorised for release by the Telix Pharmaceuticals Limited Disclosure Committee on behalf of the Board.
Legal Notices
You should read this announcement together with our risk factors, as disclosed in our most recently filed reports with the Australian Securities Exchange (ASX), U.S. Securities and Exchange Commission (SEC), including our Annual Report on Form 20-F filed with the SEC, or on our website.
The information contained in this announcement is not intended to be an offer for subscription, invitation or recommendation with respect to securities of Telix Pharmaceuticals Limited (Telix) in any jurisdiction, including the United States. The information and opinions contained in this announcement are subject to change without notification. To the maximum extent permitted by law, Telix disclaims any obligation or undertaking to update or revise any information or opinions contained in this announcement, including any forward-looking statements (as referred to below), whether as a result of new information, future developments, a change in expectations or assumptions, or otherwise. No representation or warranty, express or implied, is made in relation to the accuracy or completeness of the information contained or opinions expressed in the course of this announcement.
This announcement may contain forward-looking statements, including within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, that relate to anticipated future events, financial performance, plans, strategies or business developments. Forward-looking statements can generally be identified by the use of words such as “may”, “expect”, “intend”, “plan”, “estimate”, “anticipate”, “believe”, “outlook”, “forecast” and “guidance”, or the negative of these words or other similar terms or expressions. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to differ materially from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. Forward-looking statements are based on Telix’s good-faith assumptions as to the financial, market, regulatory and other risks and considerations that exist and affect Telix’s business and operations in the future and there can be no assurance that any of the assumptions will prove to be correct. In the context of Telix’s business, forward-looking statements may include, but are not limited to, statements about: the initiation, timing, progress and results of Telix’s preclinical and clinical trials, and Telix’s research and development programs; Telix’s ability to advance product candidates into, enrol and successfully complete, clinical studies, including multi-national clinical trials; the timing or likelihood of regulatory filings and approvals for Telix’s product candidates, manufacturing activities and product marketing activities; Telix’s sales, marketing and distribution and manufacturing capabilities and strategies; the commercialisation of Telix’s product candidates, if or when they have been approved; Telix’s ability to obtain an adequate supply of raw materials at reasonable costs for its products and product candidates; estimates of Telix’s expenses, future revenues and capital requirements; Telix’s financial performance; developments relating to Telix’s competitors and industry; and the pricing and reimbursement of Telix’s product candidates, if and after they have been approved. Telix’s actual results, performance or achievements may be materially different from those which may be expressed or implied by such statements, and the differences may be adverse. Accordingly, you should not place undue reliance on these forward-looking statements.
©2025 Telix Pharmaceuticals Limited. The Telix Pharmaceuticals®, Telix Group company, and Telix product names and logos are trademarks of Telix Pharmaceuticals Limited and its affiliates – all rights reserved. Trademark registration status may vary from country to country.
FAQ
What therapeutic candidates will be discussed in Telix Pharmaceuticals' (TLX) March 2025 investor webinar?
Who are the key opinion leaders presenting at Telix's (TLX) March 2025 urologic oncology webinar?
What is the focus of TLX591's ProstACT Global Phase 3 trial?
What will be discussed regarding TLX250 in the Telix (TLX) investor webinar?
